Investor relations
Interview with Alexandre Fraichard: ‘Bioaster will help us gain a year.’
- genOway achieved €21M in revenue in 2025 (-5%), impacted by a cautious market environment and a major commercial reorganization.
- The company accepts this slowdown in order to deploy its “Route 50+data” strategic plan and accelerate growth through the partial acquisition of Bioaster (13 hires).
- Profitability remains strong, with an EBITDA margin above 15% (16.9% in the first half of 2025), and operations in 28 countries serving 550 clients.
The ROUTE50+ strategic plan becomes ROUTE50+DATA with the acquisition of assets from an OMICS platform (data science & AI)
- ROUTE50+ becomes ROUTE50+DATA: genOway expands its strategic plan by integrating assets in data science, AI, and OMICS to enhance the predictability of preclinical data
- Financing & acceleration: the acquisition of these assets is financed by a €7 million private placement, enabling the plan to be accelerated by approximately one year with an operational platform planned for early 2026
- The company aims at an average organic growth of ~20% per year, at least €50 million in revenue by 2028, and an EBITDA margin > 15%
December 16, 2025: Dowload the press release
Accelerated development in China: genOway Shanghai as a growth driver for the Group
- The genOway Shanghai joint venture is rapidly accelerating its development in China, with growth well above initial forecasts.
- Its annualized revenue has approached ~€2 million in recent months and it is expected to reach profitability by the end of 2025
- The goal is to double revenue in 2026 and contribute between €5 million and €10 million to genOway's overall revenue by 2028
1November 18, 2026: Download the press release
genOway Investor Presentation
September 25, 2025: Download presentation
genOway accelerates the rollout of its ROUTE 50+ strategic plan, building on solid results in 2024
- Solid growth of +10% in business activity in 2024
- Second consecutive year with an EBITDA margin above 20%
- Net income of €1.8 million (up 17% compared to 2023)
March 27, 2025: Download the press release
Fighting obesity and metabolic diseases: genOway's humanized models increasingly adopted by researchers in these new markets
- The pharmaceutical industry is investing heavily in the development of new treatments targeting GLP-1R to combat obesity and metabolic disorders
- In its publication in Nature Medicine, Pfizer demonstrated the central role of this receptor in the regulation of numerous metabolic mechanisms using genOway's humanized GLP-1R model
- Launched in 2022, sales of genOway's humanized GLP1R model tripled between 2023 and 2024, providing additional growth leverage for the company and demonstrating the relevance of its product range expansion strategy.
November 4, 2024: Download the press release
2024 half-year results in line with the objectives of the new ROUTE50+ strategic plan
- Sustained growth in activity of +15%, still driven by catalog models
- EBITDA margin of 18.7%, above the minimum profitability threshold of 15% set in the ROUTE50+ financial objectives
- Cash flow from operations of €2.0 million and available cash of €4.8 million at the end of June 2024.
September 23, 2024: Download the press release
First half of 2024 up 15%, a promising sign as the new ROUTE50+ strategic plan is implemented
The company generated revenue of €10.7 million in the first half of 2024, compared with €9.3 million in the first half of 2023.
For the fifth consecutive year, genOway continues to generate double-digit organic growth semester after semester, driven by the development of its catalog model sales.
July 18, 2024: Download the press release
Strong start for the development of the genOway Shanghai joint venture in China
- Successful operational and commercial structuring
- First commercial successes
The genOway Shanghai joint venture was created in October 2023 with the aim of becoming the leading partner for preclinical research in China through the sale of immuno-oncology models from the genOway catalog. The Chinese preclinical research market, currently estimated to be the third largest in the world behind the United States and Europe, is expected to close the gap with the US leader over the next decade.
June 25, 2024: Download the press release
LETTER TO SHAREHOLDERS – JUNE 2024
- Editorials written by Christian Grenier (Chairman of the Board of Directors) and Alexandre Fraichard (Chief Executive Officer)
- Our business/2023 results – the main principles of the company's activity and its financial results
- Route50+ strategic plan – the main areas of focus, levers and financial ambitions
- Carnet de l'actionnaire / revue de Shareholder's notebook/press review – stock market data and press appearances
June 5, 2024: Download the letter to shareholders
genOway unveils Route50+, its new strategic plan aimed at building a recognized global leader in preclinical research (January 16, 2024)
- €50 million in revenue targeted by 2028, exclusively through organic growth
- External growth strategy to further accelerate development
- Minimum EBITDA margin of 15% throughout the plan
-----
